Description
This non‑competitive procurement awards a service contract to Metabolon, Inc. to perform untargeted metabolomic profiling and bioinformatic analysis on plasma samples from 30 ME/CFS patients (pre‑ and post‑phenylbutyrate treatment) and 15 healthy controls. The work includes sample processing, high‑resolution mass spectrometry, data normalization, statistical comparisons, and delivery of a comprehensive report identifying metabolites and pathways altered by disease and by treatment. The effort spans a one‑year base period (9/30/2026‑9/29/2027) with a total contract value of approximately $41.5 million.
• Perform untargeted metabolomics on 75 plasma samples using Metabolon’s proprietary platform.
• Compare baseline ME/CFS vs. healthy controls to identify disease‑associated metabolites.
• Compare post‑treatment vs. baseline to assess phenylbutyrate impact.
• Compare post‑treatment ME/CFS vs. healthy controls to evaluate normalization.
• Provide bioinformatic analysis, pathway mapping, and final deliverable report.
• Work performed at Metabolon’s Morrisville, NC facility; data must be compatible with existing NIH ME/CFS dataset.